The new announcement that the stem cell therapy trial at Moorefield Hospital has been successful for AMD is exciting . As you know details are limited yet other than they are still someway (a long way) from making this treatment available to everyone and more trials are planned. However, if you are in or near London, the September 2016 conference is open to anyone who buys a ticket. And some members of the forum may be interested to attend as I am sure more helpful and interesting details will be available then? Just wanting to share and remind you of this information
I am new to this forum. Forgive me if I am... - Macular Society
I am new to this forum. Forgive me if I am not obeying the rules. But this is very interesting for many I think.
Thank you for sharing this information with us Caroline. I will not be able to attend personally, but I am very interested in finding out more about stem cell research. I suffer from myopic CNV and normally treatments are researched on and become available for AMD sufferers first and eventually filter down to us as myopic CNV is much less common but fortunately, so far, the same treatments seem to work for both. Lets hope we can all be kept ticking along on our Lucentis and Eylea etc until a longer-term solution can be found. Whether your post is within the rules or not, a bit of hope for the future is always a good thing.
Stem cell therapy had been done successfully in the USA- (private trial in Florida)and now in Moorefields Hospital in London. Maybe elsewhere too- but I don't know about those successes. It was on TV as well as all over the Internet. One Gentlemans vision went from legally blind to being able to drive. I will try and find the links for you. So we know it can be done... Just need it to go through all the trials and be safe and available - Super quick please!
patientsforstemcells.org/ad...
This isn't the link I originally read but - it still does give the basic details of the SCOTS stem cell trial in Florida for macular degeneration and some of the successes. Clearly, it's aimed at an American audience, but still the cases highlighted are exciting I thought . Happy reading !